Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Clinical trial NCT00844064 · COMPLETED

Trial details

NCT number: NCT00844064
Sponsor: Isarna Therapeutics GmbH
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Neoplasms Melanoma Colorectal Neoplasms

Start date: 2005-01-01
Primary completion: 2011-11-01
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.